ClinicalTrials.gg
RecruitingNCT07539311RAINFOL-09Updated Nov 3, 2026

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

A Phase 2 interventional study of Rina-S in Gastrointestinal Cancers, sponsored by Genmab. Recruiting at 28 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genmab · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 3, 2026First sites in 9 new countries22 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.

Planned enrollment
62nd of 245
160 · median 60
Started
2026
with 15 others
Phase 2
42 of 316
8 open now
Primary completion
2028-09
later than 86 of 113 live
Registered
309th of 316
by date

Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 62nd largest by planned enrollment of the 245 interventional ones that give a count, is one of 16 that started in 2026, is one of 42 in phase 2, reaches primary completion later than 86 of the 113 other live ones, and was the 309th registered.

Gastrointestinal Neoplasms

696 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 122 (76%) set no upper age limit and 18 (11%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Gastrointestinal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 study will be conducted in different countries around the world with up to about 160 participants.

The purpose of this study is to evaluate how well Rina-S works against GI cancers.

The medication in this study is Rina-S monotherapy (by itself; no other cancer treatments). All participants will receive active drug; no one will be given placebo.

Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.

The duration of the study will be different for every participant, but an average study duration of 22 months is expected for participants. This will include a treatment period (expected to last an average of 12 months), plus data collection periods before and after treatment. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of an individual cycle is 21 days). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.

Read the detailed description

This is a Phase 2, open-label, multicenter, multi-cohort trial to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of Rina-S as monotherapy in participants with GI cancers who have progressed on or after prior standard of care (SoC) therapies.

03

Conditions studied

  • Gastrointestinal Cancers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • All study cohorts
  • Participant has or cytologically confirmed GI cancer.
  • Participant has documented or unresectable disease, not amenable to treatment with curative intent.
  • Participant has per the (RECIST) version 1.1 at baseline.
  • Participant must have radiological disease progression while on or after receiving the most recent regimen.
  • Participant has (ECOG) performance status of 0 or 1.
  • Participant has ≥3 months.
  • Participant must be able to provide a newly obtained or sample.
  • Participant must have adequate organ and bone marrow function, per laboratory test results prior to Rina-S administration.

Key Exclusion Criteria (all study cohorts):

  • Participant has non-malignant gastrointestinal disorders, including but not limited to, diarrhea > grade 1, ulcerative colitis, inflammatory bowel disease.
  • Participants with recent (up to 4 weeks) history of significant gastrointestinal bleeding, current cancer related ulcerations, fistula, abscess or recent perforation (within 4 to 6 weeks).
  • Participant has a past or current other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy.
  • Participants with newly identified or known unstable (eg, progressing ) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as ).
  • Prior treatment with topoisomerase-1 inhibitor containing antibody-drug conjugate (ADC).
  • Treatment with an anticancer agent within 28 days prior to the first dose of trial treatment.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Rina-S

    Participants with GI cancer in cohorts A-E will receive Rina-S at the specified dose.

    Biological: Rina-S

Interventions

  • BiologicalRina-S

    Intravenous (IV) administration.

    Also known as: Rinatabart sesutecan, GEN1184, PRO1184

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR)

    Time frame: Up to approximately 22 months

Secondary outcomes

  1. Duration of Response (DOR)

    Time frame: Up to approximately 22 months

  2. Disease Control Rate (DCR)

    Time frame: Up to approximately 22 months

  3. Progression-free Survival (PFS)

    Time frame: Up to approximately 22 months

  4. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 22 months

  5. Maximum Concentration (Cmax) of Rina-S Related Analytes

    Time frame: Up to approximately 12 months

  6. Area Under the Concentration-time Curve (AUC) of Rina-S Related Analytes

    Time frame: Up to approximately 12 months

  7. Time to Reach Cmax (Tmax) of Rina-S Related Analytes

    Time frame: Up to approximately 12 months

07

Study locations

28 of 28 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Sep 2028, 28 months after the start.

Of 55 phase 2 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartActual
May 11, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Nov 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
22 sites added — first sites in Australia, France, South Korea, United Kingdom, Belgium and 4 more
All 9 countries

Australia, France, South Korea, United Kingdom, Belgium, Germany, Netherlands, Spain, Taiwan

Show 22 added (5 United States, 5 France, 3 Australia, 2 United Kingdom, 2 Belgium, 1 South Korea, 1 Germany, 1 Netherlands, 1 Spain, 1 Taiwan)
  • USC Norris Comprehensive Cancer Center · Los Angeles, United States
  • UCLA Hematology/Oncology, Santa Monica · Santa Monica, United States
  • University of Colorado Hospitak Anschutz · Aurora, United States
  • Moffitt Cancer Center · Tampa, United States
  • Greco-Hainsworth Center for Research · Nashville, United States
  • St John of God Subiaco Hospital · Subiaco, Australia
  • Cancer Research SA Pty Ltd · Adelaide, Australia
  • CHU Brest Cavale Blanche · Brest, France
  • Hôpital Saint-Antoine Onco Med · Paris, France
  • Samsung Medical Center · Seoul, South Korea
  • Hammersmith Hospital · London, United Kingdom
  • GenesisCare St Leonards · Saint Leonards, Australia
  • Cliniques Universitaires Saint-Luc | Cliniques Universitaires Saint-Luc|Head and Neck tumors, Route 407 | Cliniques Universitaires Saint-Luc|Hematology · Brussels, Belgium
  • Centre Hospitalier de l'Ardenne|Service Oncologie · Libramont, Belgium
  • Institut Régional du Cancer de Montpellier · Montpellier, France
  • Hôpital Européen Georges Pompidou · Paris, France
  • Centre Leon Berard · Lyon, France
  • Asklepios Klinik Altona · Hamburg, Germany
  • Amsterdam UMC, Locatie VUMC|Hematology · Amsterdam, Netherlands
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Taipei Veterans General Hospital · Taipei, Taiwan
  • University College London Hospitals · London, United Kingdom
across 2 updates, Oct 6, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    11 sites added — first sites in Belgium, Germany, Netherlands, Spain and Taiwan
    Show 11 added (3 France, 2 Belgium, 1 Australia, 1 Germany, 1 Netherlands, 1 Spain, 1 Taiwan, 1 United Kingdom)
    • GenesisCare St Leonards · Saint Leonards, Australia
    • Cliniques Universitaires Saint-Luc | Cliniques Universitaires Saint-Luc|Head and Neck tumors, Route 407 | Cliniques Universitaires Saint-Luc|Hematology · Brussels, Belgium
    • Centre Hospitalier de l'Ardenne|Service Oncologie · Libramont, Belgium
    • Institut Régional du Cancer de Montpellier · Montpellier, France
    • Hôpital Européen Georges Pompidou · Paris, France
    • Centre Leon Berard · Lyon, France
    • Asklepios Klinik Altona · Hamburg, Germany
    • Amsterdam UMC, Locatie VUMC|Hematology · Amsterdam, Netherlands
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Taipei Veterans General Hospital · Taipei, Taiwan
    • University College London Hospitals · London, United Kingdom
  2. Oct 6, 2026
    11 sites added — first sites in Australia, France, South Korea and United Kingdom
    Show 11 added (5 United States, 2 Australia, 2 France, 1 South Korea, 1 United Kingdom)
    • USC Norris Comprehensive Cancer Center · Los Angeles, United States
    • UCLA Hematology/Oncology, Santa Monica · Santa Monica, United States
    • University of Colorado Hospitak Anschutz · Aurora, United States
    • Moffitt Cancer Center · Tampa, United States
    • Greco-Hainsworth Center for Research · Nashville, United States
    • St John of God Subiaco Hospital · Subiaco, Australia
    • Cancer Research SA Pty Ltd · Adelaide, Australia
    • CHU Brest Cavale Blanche · Brest, France
    • Hôpital Saint-Antoine Onco Med · Paris, France
    • Samsung Medical Center · Seoul, South Korea
    • Hammersmith Hospital · London, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07539311
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
May 11, 2026
Primary completion
Sep 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rinatabart sesutecan

Start the discussion